Abstract 100P
Background
Colorectal cancer ranks as the third most prevalent cancer globally and stands as the second primary contributor to cancer-related mortality. Utilization of a phenomic data approach allows researchers to reveal the mechanisms and molecular pathogenesis of colorectal cancer. We aimed to investigate the correlation between the phenomic features and colorectal cancer in a large cohort study.
Methods
We included 502369 subjects aged 37-73 years in the UK Biobank recruited since 2006. In total, 59 parameters exploring socio-demographic factors, blood chemistry, anthropometric measurements and lifestyle factors of participants collected at baseline assessment were analysed. Univariate and multivariate logistic regression were conducted to examine the associations of these parameters with colorectal cancer risk, based on the odds ratio (OR) and 95% confidence intervals (CI).
Results
The analysis included a total of 438625 participants, of which 5436 (1.2%) were incident colorectal cancer cases and 433189 were healthy controls. A marker, cystatin C was associated with colorectal cancer (adjusted OR 2.11; 95% CI 1.92-2.32). Compared to Asians, Whites ethnicity had higher risk of developing colorectal cancers (adjusted OR 2.54; 95% CI 1.93-3.34). In addition to colorectal cancer, Cystatin C and ethnicity are consistently associated with total gastrointestinal cancers. Cystatin C and ethnicity appear to be important features in GI cancers, suggesting some overlap in the molecular pathogenesis of GI cancers.
Conclusions
Cystatin C and ethnicity emerged as a consistent biomarker associated with different types of gastrointestinal cancers, including colorectal cancer. In order to provide more in-depth understanding of how these factors were associated with gastrointestinal cancers and shed light on the molecular pathogenesis of gastrointestinal cancers, future research will employ a multi-modal approach exploring the genomics and proteomics of the UK Biobank cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract